Standish Fleming is a co-founder of San Diego’s Forward Ventures and a 24-year veteran of early-stage life sciences investing. He has helped raise and manage six venture funds totaling more than $500 million and served on the boards of 19 venture-backed companies, including Nereus Pharmaceuticals, Ambit Biosciences, Triangle Pharmaceuticals (acquired by Gilead Sciences) and Actigen/Corixa (now part of GSK). He currently serves as a director of Ambit Biosciences and is a founding director of Nereus Pharmaceuticals. At Forward, Mr. Fleming has made investments in almost every segment of the health-care industry, including pharmaceuticals, biologics, diagnostics, devices, services and software. He has managed both platform and product companies/investments in the portfolio and led or participated in financings at all levels from pre-start-up to PIPES in public companies, in both debt and equity.
As Washington grapples with the deficit, nothing generates more emotion than tax “loopholes.” A priority “loophole” target in the budget that President Obama sent to Congress last week is the treatment... Read more »